Partnership / Collaboration · GCC · Announced 30 Apr 2024
Kelix Bio → Khalifa University of Science & Technology + Mubadala Investment
Partnership / Collaboration deal between Kelix Bio (United Arab Emirates) and Khalifa University of Science & Technology + Mubadala Investment (United Arab Emirates), announced 30 Apr 2024. Value: Undisclosed.
Parties: KELIX BIO (United Arab Emirates) → Khalifa University of Science & Technology + Mubadala Investment Company (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- United Arab Emirates (Abu Dhabi-centered: KU and Mubadala are Abu Dhabi; KELIX is DIFC/Dubai). Ties into KU's Center for Biotechnology and its UAE reference-genome work.
- Therapeutic area
- Multi-therapy
- Asset
- No specific molecule. Scope is joint R&D: identifying, evaluating and developing life-science technologies and therapies; KELIX's modalities span new chemical entities, biologics and ATMPs; plus strengthening regional supply chains for vaccines and therapeutics.
- Announced
- 30 Apr 2024
Our analysis
Why this matters.
Read alone, this is a modest research MoU. Read in context, it's one deliberate move in Mubadala's systematic construction of a UAE life-sciences champion.
The full analysis is free to read with a work email on this page.
Source: Khalifa University